Help Clarify Invokana's New Indication to Reduce Major Cardiac Events

Reps will promote Invokana (canagliflozin) as the first flozin approved to reduce major CV events in type 2 diabetes.

Jardiance (empagliflozin) is already approved to reduce CV DEATH in type 2 diabetes patients with established CV disease.

Now Invokana labelling will say it reduces major CV events in these patients. This is a case of labelling catching up with the evidence. But help clarify this new indication.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote